|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 329.00 SEK | +1.04% |
|
-1.97% | -1.14% |
| 01-19 | SEB Raises Price Target for Sobi to 500 Kronor (400), Reiterates Buy | FW |
| 01-16 | Sobi's Rare Kidney Diseases Drug Lands Approval in Europe | MT |
| Capitalization | 113B 12.45B 10.64B 9.88B 9.27B 17.19B 1,140B 18.41B 44.87B 539B 46.68B 45.73B 1,969B | P/E ratio 2025 * |
-650x | P/E ratio 2026 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise value | 124B 13.58B 11.61B 10.78B 10.11B 18.75B 1,244B 20.08B 48.95B 588B 50.92B 49.88B 2,147B | EV / Sales 2025 * |
4.34x | EV / Sales 2026 * | 3.71x |
| Free-Float |
51.66% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Swedish Orphan Biovitrum AB
| 1 day | +1.04% | ||
| 1 week | -1.97% | ||
| Current month | -1.14% | ||
| 1 month | +0.30% | ||
| 3 months | +7.59% | ||
| 6 months | +21.13% | ||
| Current year | -1.14% |
| 1 week | 322 |  | 360.6 |
| 1 month | 322 | | 360.6 |
| Current year | 322 | | 360.6 |
| 1 year | 241.8 | | 360.6 |
| 3 years | 197.9 | | 360.6 |
| 5 years | 127.1 | | 360.6 |
| 10 years | 89.5 | | 360.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 61 | 2017-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 59 | 2018-07-19 |
| Chief Tech/Sci/R&D Officer | 55 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Staffan Schüberg
BRD | Director/Board Member | 57 | 2019-12-31 |
| Director/Board Member | 70 | 2020-12-31 | |
Filippa Stenberg
BRD | Director/Board Member | - | - |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.07% | 1.15% | 295 M€ | |
| +1.59% | 0.9% | 4 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.04% | -1.97% | -0.90% | +43.17% | 12.31B | |
| +2.12% | -1.26% | +9.94% | +3.79% | 75.29B | |
| -2.45% | +87.30% | +87.30% | +87.30% | 60.19B | |
| +0.94% | +2.47% | -34.98% | -40.42% | 57.45B | |
| -1.37% | -0.51% | +38.08% | +229.21% | 57.16B | |
| +4.38% | -3.19% | +22.82% | -39.59% | 24.26B | |
| +2.00% | +1.20% | +45.52% | +25.81% | 20.15B | |
| -0.60% | -7.44% | +166.34% | +91.88% | 18.51B | |
| -22.35% | -21.78% | +17.27% | +998.53% | 17.42B | |
| +15.84% | +25.78% | +46.24% | -74.32% | 16.8B | |
| Average | -1.12% | -4.12% | +39.76% | +132.53% | 35.95B | |
| Weighted average by Cap. | -0.46% | -3.05% | +32.78% | +95.28% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 28.53B 3.13B 2.68B 2.49B 2.33B 4.32B 287B 4.63B 11.29B 136B 11.74B 11.5B 495B | 31.66B 3.48B 2.97B 2.76B 2.59B 4.8B 318B 5.14B 12.53B 150B 13.03B 12.77B 550B |
| Net income | -253M -27.75M -23.72M -22.02M -20.65M -38.32M -2.54B -41.03M -100M -1.2B -104M -102M -4.39B | 5.7B 625M 535M 496M 465M 863M 57.27B 925M 2.25B 27.07B 2.34B 2.3B 98.87B |
| Net Debt | 10.3B 1.13B 967M 897M 842M 1.56B 104B 1.67B 4.08B 48.95B 4.24B 4.15B 179B | 3.97B 436M 373M 346M 325M 602M 39.93B 645M 1.57B 18.87B 1.63B 1.6B 68.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-21 | 329.00 kr | +1.04% | 328,096 |
| 26-01-20 | 325.60 kr | -0.85% | 289,241 |
| 26-01-19 | 328.40 kr | -0.97% | 433,655 |
| 26-01-16 | 331.60 kr | -2.47% | 525,975 |
| 26-01-15 | 340.00 kr | -0.41% | 1,363,173 |
Delayed Quote Nasdaq Stockholm, January 21, 2026 at 12:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition